PDCD1LG2 and asthma: Theoretically, the administration of PD-1 inhibitors blocks the PD-1–PD-L2 pathway, enhancing PD-L2 function and leading to increased production of Th2 cytokines [36], which could result in Th2 inflammation-related asthma.